Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2021-02-09 Sale |
2021-02-10 8:17 pm |
Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer |
35,000 | $6.75 | $236,250 | 837,000 (Direct) |
View |
| 2021-02-08 Sale |
2021-02-09 4:00 pm |
Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer |
40,792 | $6.5 | $265,148 | 872,000 (Direct) |
View |
| 2020-08-18 Sale |
2020-08-19 08:55 am |
Aquestive Therapeutics Inc. | AQST | Maxwell John T. SVP-Chief Financial Officer |
3,000 | $8 | $24,000 | 150,614 (Direct) |
View |
| 2020-06-04 Sale |
2020-06-05 4:05 pm |
Aquestive Therapeutics Inc. | AQST | Kendall Keith J CEO and President |
50,000 | $5.1062 | $255,310 | 638,964 (Direct) |
View |
| 2020-05-08 Sale |
2020-05-11 4:15 pm |
Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer |
40,000 | $5 | $200,000 | 902,113 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2021-03-11 Option Award |
2021-03-15 5:10 pm |
N/A 2031-03-11 |
Aquestive Therapeutics Inc. | AQST | BRAENDER LORI J SVP, General Counsel |
75,000 | $0 | 75,000 (Direct) |
View |
| 2021-03-11 Option Award |
2021-03-15 5:10 pm |
N/A 2031-03-11 |
Aquestive Therapeutics Inc. | AQST | Taglietti Marco Director |
28,500 | $0 | 28,500 (Direct) |
View |
| 2021-03-11 Option Award |
2021-03-15 5:10 pm |
N/A 2031-03-11 |
Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer |
70,000 | $0 | 70,000 (Direct) |
View |
| 2021-03-11 Option Award |
2021-03-15 5:10 pm |
N/A 2031-03-11 |
Aquestive Therapeutics Inc. | AQST | Barber Daniel SVP-Chief Operating Officer |
100,000 | $0 | 100,000 (Direct) |
View |
| 2021-03-11 Option Award |
2021-03-15 5:10 pm |
N/A 2031-03-11 |
Aquestive Therapeutics Inc. | AQST | Boyd Peter E. SVP-Bus. Process & Info. Tech. |
35,000 | $0 | 35,000 (Direct) |
View |
| 2020-12-30 Gift |
2021-01-04 4:05 pm |
N/A N/A |
Aquestive Therapeutics Inc. | AQST | Kendall Keith J CEO and President |
1,000 | $0 | 638,149 (Direct) |
View |
| 2020-06-30 Exercise |
2020-07-02 4:00 pm |
2020-06-30 N/A |
Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer |
333 | $0 | 912,792 (Direct) |
View |
| 2020-06-30 Tax Withholding |
2020-07-02 4:00 pm |
N/A N/A |
Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer |
94 | $4.86 | 912,792 (Direct) |
View |
| 2020-06-30 Exercise |
2020-07-02 4:00 pm |
2020-06-30 N/A |
Aquestive Therapeutics Inc. | AQST | Kendall Keith J CEO and President |
333 | $0 | 639,149 (Direct) |
View |
| 2020-06-30 Tax Withholding |
2020-07-02 4:00 pm |
N/A N/A |
Aquestive Therapeutics Inc. | AQST | Kendall Keith J CEO and President |
148 | $4.86 | 639,149 (Direct) |
View |
| 2020-06-16 Option Award |
2020-06-18 5:12 pm |
2021-06-16 2030-06-16 |
Aquestive Therapeutics Inc. | AQST | BROWN GREGORY B Director |
14,000 | $0 | 89,085 (Direct) |
View |
| 2020-06-16 Option Award |
2020-06-18 4:05 pm |
2021-06-16 2030-06-16 |
Aquestive Therapeutics Inc. | AQST | Scibetta James S Director |
14,000 | $0 | 45,635 (Direct) |
View |
| 2020-06-16 Option Award |
2020-06-18 4:05 pm |
2021-06-16 2030-06-16 |
Aquestive Therapeutics Inc. | AQST | Lurker Nancy Director |
14,000 | $0 | 14,000 (Direct) |
View |
| 2020-06-16 Option Award |
2020-06-18 4:05 pm |
2021-06-16 2030-06-16 |
Aquestive Therapeutics Inc. | AQST | COSTA SANTO J Director |
14,000 | $0 | 31,327 (Direct) |
View |
| 2020-06-16 Option Award |
2020-06-18 4:05 pm |
2021-06-16 2030-06-16 |
Aquestive Therapeutics Inc. | AQST | BRATTON DOUGLAS K Director 10% Owner |
14,000 | $0 | 11,592,379 (Direct) |
View |
| 2020-06-16 Option Award |
2020-06-18 4:05 pm |
2021-06-16 2030-06-16 |
Aquestive Therapeutics Inc. | AQST | Cochran John Director |
14,000 | $0 | 89,085 (Direct) |
View |
| 2020-05-31 Tax Withholding |
2020-06-02 5:14 pm |
N/A N/A |
Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer |
4,132 | $4.87 | 912,553 (Direct) |
View |
| 2020-05-31 Exercise |
2020-06-02 5:14 pm |
2020-05-31 N/A |
Aquestive Therapeutics Inc. | AQST | Schobel Alexander Mark Chief Innovation/Tech Officer |
14,572 | $0 | 912,553 (Direct) |
View |
| 2020-05-31 Tax Withholding |
2020-06-02 5:13 pm |
N/A N/A |
Aquestive Therapeutics Inc. | AQST | Kendall Keith J CEO and President |
6,492 | $4.87 | 688,964 (Direct) |
View |
| 2020-05-31 Exercise |
2020-06-02 5:13 pm |
2020-05-31 N/A |
Aquestive Therapeutics Inc. | AQST | Kendall Keith J CEO and President |
14,572 | $0 | 688,964 (Direct) |
View |